Effects of low dose ultraviolet A‐1 phototherapy on morphea
CJ Gruss, G Von Kobyletzki… - Photodermatology …, 2001 - Wiley Online Library
Aim: The effects of low dose ultraviolet A‐1 (UVA‐1) phototherapy on different clinical stages
of morphea (localized scleroderma) were analyzed in this case study. Based on these data …
of morphea (localized scleroderma) were analyzed in this case study. Based on these data …
Recent advances in phototherapy
JC Simon, D Pfieger, E Schöpf - European Journal of Dermatology, 2000 - jle.com
This synopsis reviews recent developments in dermatological phototherapy. UVA1
phototherapy (340-400 nm) is effective in the treatment of inflammatory skin diseases such …
phototherapy (340-400 nm) is effective in the treatment of inflammatory skin diseases such …
Parenteral administration of 8-methoxypsoralen in photopheresis
RM Knobler, F Trautinger, W Graninger… - Journal of the American …, 1993 - Elsevier
Background: Extracorporeal photochemotherapy (EP) is used for the treatment of cutaneous
T-cell lymphoma (CTCL), progressive systemic sclerosis (PSS), pemphigus vulgaris, and …
T-cell lymphoma (CTCL), progressive systemic sclerosis (PSS), pemphigus vulgaris, and …
Extracorporeal photopheresis: past, present, and future
R Knobler, ML Barr, DR Couriel, JLM Ferrara… - Journal of the American …, 2009 - Elsevier
Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-
methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological …
methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological …
Photopheresis: clinical applications and mechanism of action
AH Rook, KR Suchin, DMF Kao, EK Yoo… - Journal of Investigative …, 1999 - Elsevier
Photopheresis is a leukapheresis-based therapy that utilizes 8-methoxypsoralen and
ultraviolet A irradiation. Photopheresis is currently available at approximately 150 medical …
ultraviolet A irradiation. Photopheresis is currently available at approximately 150 medical …
Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis
A Kreuter, F Breuckmann, A Uhle, N Brockmeyer… - Journal of the American …, 2004 - Elsevier
BACKGROUND: Increased collagen synthesis, vascular damage, and T-lymphocytic
infiltration contribute to the development of systemic sclerosis. Preliminary studies revealed …
infiltration contribute to the development of systemic sclerosis. Preliminary studies revealed …
Extracorporeal photochemotherapy induces the production of tumor necrosis factor-α by monocytes: implications for the treatment of cutaneous T-cell lymphoma and …
BR Vowels, M Cassin, MH Boufal, LJ Walsh… - Journal of investigative …, 1992 - Elsevier
Extracorporeal photopheresis (ExP) has been shown to be an efficacious and well-tolerated
therapy in the treatment of cutaneous T-cell lymphoma (CTCL) and systemic sclerosis …
therapy in the treatment of cutaneous T-cell lymphoma (CTCL) and systemic sclerosis …
Evidence‐based practice of photopheresis 1987–2001: a report of a workshop of the British Photodermatology Group and the UK Skin Lymphoma Group
KE McKenna, S Whittaker, LE Rhodes, P Taylor… - 2006 - academic.oup.com
Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory
therapy which involves separation of the patient's leucocyte‐rich plasma, followed by ex vivo …
therapy which involves separation of the patient's leucocyte‐rich plasma, followed by ex vivo …
Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease
PC Pinton, F Porta, T Izzi, M Venturini… - …, 2003 - haematologica.org
BACKGROUND AND OBJECTIVES: Standard or investigative immunosuppressive
therapies for cutaneous chronic graft-versus-host disease (GVHD) may prove not only …
therapies for cutaneous chronic graft-versus-host disease (GVHD) may prove not only …
PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease
K Ghoreschi, P Thomas, M Penovici, J Ullmann… - European Journal of …, 2008 - jle.com
Chronic graft-versus-host disease (GVHD) is almost always associated with skin diseases
appearing either as lichenoid GVHD, sclerodermatous GVHD (sGVHD) or as eosinophilic …
appearing either as lichenoid GVHD, sclerodermatous GVHD (sGVHD) or as eosinophilic …